PDCD1 and hepatocellular carcinoma: Although results concerning combination therapy with anti-PD-L1/PD1 inhibitors and angiogenenic therapy have been impressive, some crucial issues persist, such as validation in Western patients, because they present a different molecular profile of HCC (75% of patients in GO3014 were Asian and 40% of patients were Asian (excluding Japan)).